US84763A1088 - Common Stock
SPECTRUM PHARMACEUTICALS INC
NASDAQ:SPPI (7/31/2023, 7:00:02 PM)
After market: 1.04 +0.01 (+0.97%)1.03
0 (0%)
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. The company is headquartered in Henderson, Nevada and currently employs 86 full-time employees. The firm is focused on acquiring, developing, and commercializing targeted oncology therapies. The firm's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
SPECTRUM PHARMACEUTICALS INC
11500 S Eastern Ave Ste 240
Henderson NEVADA 89052
P: 17028356300.0
CEO: Joseph W. Turgeon
Employees: 86
Website: https://www.sppirx.com/
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Spectrum Pharmaceuticals press release (NASDAQ:SPPI): Q1 GAAP EPS of -$0.02 beats by $0.03.Revenue of $15.6M beats by $1.44M.
Here you can normally see the latest stock twits on SPPI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: